BCR-ABL p210融合基因阳性急性髓系白血病一例并文献复习  

Acute myeloid leukemia with BCR-ABL p210 fusion gene-positive:report of one case and review of literature

作　　者：黄菊[1] 韩艳霞[1] 卫仿仙 沈闪华 胡蓓莉[1] 陈丽花[1] 王宙政[1] Huang Ju;Han Yanxia;Wei Fangxian;Shen Shanhua;Hu Beili;Chen Lihua;Wang Zhouzheng(Department of Hematology,the Second Hospital of Jiaxing,the Second Affiliated Hospital of Jiaxing College,Jiaxing 314000,China)

机构地区：[1]浙江省嘉兴学院附属第二医院,嘉兴市第二医院血液内科,314000

出　　处：《白血病．淋巴瘤》2020年第3期175-178,共4页Journal of Leukemia & Lymphoma

摘　　要：目的探讨BCR-ABL p210融合基因阳性急性髓系白血病的临床特点。方法对嘉兴市第二医院确诊的1例BCR-ABL p210融合基因阳性急性髓系白血病患者的临床特征进行分析,并复习相关文献。结果通过反转录聚合酶链反应(RT-PCR)及荧光原位杂交(FISH)等方法检测到该例患者存在费城染色体(Ph)及BCR-ABL p210融合基因,给予伊马替尼联合多药静脉化疗,疗效不佳。结论Ph^+/BCR-ABL^+急性髓系白血病患者临床少见,预后极差,目前无统一标准治疗方案。酪氨酸激酶抑制剂疗效尚不明确,联合化疗及造血干细胞移植有望改善预后。Objective To investigate the clinical characteristics of acute myeloid leukemia with BCR-ABL p210 fusion gene-positive.Methods The clinical characteristics of a patient diagnosed in the Second Hospital of Jiaxing were analyzed and the related literature was reviewed.Results BCR-ABL p210 fusion gene and Philadelphia chromosome(Ph)were detected by reverse transcription-polymerase chain reaction(RT-PCR)and fluorescence in situ hybridization(FISH).Imatinib associated with multi-drug intravenous chemotherapy resulted in poor efficacy.Conclusions Patient with Ph+/BCR-ABL+acute myeloid leukemia is rare with a very poor prognosis.There is no unified standard treatment and the efficacy of tyrosine kinase inhibitors is unclear.Intravenous chemotherapy combined with hematopoietic stem cell transplantation is expected to change the prognosis.

关 键 词：白血病 髓样 急性 费城染色体 BCR-ABL融合基因 酪氨酸激酶抑制剂 

分 类 号：R733[医药卫生—肿瘤]